Lubrizol Corporation has announced the acquisition of Bavaria Medizin Technologie GmbH (BMT) by its German subsidiary Lubrizol Deutschland GmbH from its current majority shareholder Custos Vermögensverwaltungs GmbH as well as from the minority shareholders. Financial details were not disclosed.
BMT is a designer and manufacturer of both intravascular (coronary, peripheral, and cranial) and non-vascular devices, including drug-coated balloons. With over 100 employees, the company is headquartered near Munich, Germany, and operates a manufacturing facility in Sibiu, Romania. A pioneer in catheter-based technologies, BMT developed the first commercial drug-coated balloon, the Paccocath catheter. Today, BMT holds over 50 patents and continues to innovate through self-funded R+D projects, as well as contract R+D services. Additionally, BMT offers private label manufacturing of proprietary catheters and balloons along with OEM services, which include the manufacturing of subassemblies and components, sterilisation, packaging and labelling, stent crimping, and logistics management.
According to Lubrizol, this acquisition builds upon its expertise in precision thermoplastic extrusion and product development, establishing the company as a true end-to-end partner to the global medical device and pharmaceutical industries. The acquisition expands its product design, development, and manufacturing capabilities and provides access to proprietary catheter and balloon technologies. BMT’s experience and reputation in the drug-coated balloon (DCB) space aligns well with Lubrizol’s pharmaceutical CDMO business, the company said.
“Lubrizol continues to invest in opportunities that position us as a full-service development partner for innovative OEMs in the interventional space,” said Uwe Winzen, general manager of the Health business of Lubrizol Life Science. “Our customers will benefit from additional design capabilities, an increased global footprint, and synergies with our existing formulation and manufacturing services.”